Sold as a supplement, not an FDA-approved drug. This page is educational information only, not medical advice.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Bonito peptides

Supplement

Fish-derived bioactive peptides

Also known as: katsuobushi oligopeptide

Evidence score

29/ 100

Thin evidence

Very thin human evidence

Regulatory standing. Sold as a supplement, not an approved drug
Limited human data. Some human data exists, not conclusive
No registered human trials. Nothing registered on ClinicalTrials.gov
No sources. Nothing cited to verify

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Bonito peptides are short protein fragments made by enzymatically breaking down dried bonito fish (katsuobushi) and are sold as a dietary supplement. Some of these peptides are thought to inhibit angiotensin-converting enzyme (ACE), which is the proposed basis for interest in blood pressure support.

What the evidence shows

Automatic summaryLimited human data

The facts gathered show no registered human trials and only one published paper in the database checked, so any benefit in humans is not established. Some small studies of bonito-derived peptides may exist in other literature, but how strong or consistent that evidence is remains unclear from these records.

This name is shared with unrelated compounds in public databases, so trial and paper counts are not shown here, and the evidence score counts no registered trials. Treat this profile as a starting point only.

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.